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ABSTRACT
Objective: Controlled release floating tablets require excipients, which act as a matrix to control the release of the active drug and facilitate 
the tablet floating in the gastric milieu. One potential excipient is coprocessed excipients of xanthan gum and acacia gum (Co-XG-GA), which is 
a physical modification of the two natural polymers. In this study, we produced several Co-XG-GA and used them as matrices in floating tablet 
formulations.
Methods: Several coprocessed excipients were prepared from xanthan gum and acacia gum at ratios of 1:1, 1:2, 2:1, 1:3, and 3:1. The obtained 
excipients were then characterized physically, chemically, and functionally. The coprocessed excipients were then formulated in floating tablets using 
famotidine as the drug model. The floating tablets were then evaluated in terms of the tablet floating capabilities and the drug release in HCl medium 
at pH 1.2 for 8 h.
Results: Our results showed that the coprocessed excipients were a fine powder, odorless, and a grayish-white color. The excipients had a good 
swelling index, fairly large viscosity, and good gel strength; hence, they were suitable to be applied as the matrices of floating tablet formulations. The 
floating tablets of F2, which contained the Co-XG-GA 1:2, demonstrated the best characteristics with 8.33±0.58 min of floating lag time and 24 h of 
total floating time. Further release studies revealed that the famotidine floating tablets, which used Co-XG-GA (F1–F5) as matrices, controlled drug 
release with zero-order release kinetics and could be used for controlled release dosage forms.
Conclusion: Collectively, our results indicate that the Co-XG-GA can be applied as matrices in controlled release floating tablets.
Keywords: Acacia gum, Coprocessed excipient, Famotidine, Floating tablet, Xanthan gum.
INTRODUCTION
Pharmaceutical preparations with gastroretentive drug delivery system 
are one of the ongoing developments to overcome absorption and 
bioavailability problems that often occur in ordinary oral dosage forms. 
This is partAicularly true for drugs with large absorption in certain 
areas of the digestive tract. Floating drug delivery systems (FDDSs) are 
delivery systems based on preparations that float in the gastric fluid 
due to their lower densities compared with gastric fluid. Accordingly, 
these preparations remain buoyant in the stomach for a long period 
without affecting the gastric emptying rate [1,2].
There are various types of natural gums, including those derived from 
natural polymers such as the natural polysaccharides, xanthan gum and 
acacia gum. Xanthan gum has good flow properties and is considered 
stable and non-toxic. In addition, it is a good gelling and viscosity-
increasing agent (viscosity enhancer). Xanthan gum also has high 
swelling properties due to large water absorption and slight erosion [3]. 
However, xanthan gum has the disadvantage that it is not a tablet 
binder. In contrast, acacia gum is a stable material, a good gelling agent, 
and behaves like a tablet binder, but it has swelling properties with 
low viscosity. However, acacia gum is unique because it forms colloidal 
solutions with low viscosity compared with other gums. To obtain 
better overall characteristics of the two excipients, a modification of the 
coprocessed excipients of xanthan gum and acacia gum (Co-XG-GA) was 
performed. Modification of the coprocess was performed by combining 
the two excipients in the form of solution dispersion using a codrying 
process. The purposes of the coprocess excipient were to increase 
synergy and functionality, change the physicochemical properties, and 
cover the shortcomings of each of its constituent excipient [4,5]. The 
coprocess excipient obtained from the xanthan gum and acacia gum 
was then used as a matrix in floating tablet formulations.
Famotidine, which is one of the drugs absorbed in the stomach, was 
used as the drug model in this study. Famotidine is a histamine 2 (H2) 
receptor blocker with low bioavailability, ranging from 40% to 45% on 
oral administration. In addition, famotidine has an elimination half-
life of 2.5–4 h. Drugs such as famotidine are suitable for preparation 
in the FDDS because they allow delivery to the H2 receptors found in 
gastric parietal cells. Famotidine in the form of FDDS serves to reduce 
the known side effects of famotidine, including diarrhea, dizziness, 
headache, and anorexia. This is because famotidine is in a sustained 




Famotidine was gifted by Molex Ayus Co. Ltd. (Indonesia). Xanthan 
gum was purchased from Cargill Bioengineering (Canada). Acacia gum 
was purchased from Shangqiu Kangmedia Bio-Tech (China). Other 
chemicals and solvents were of analytical grade and purchased from 
commercial suppliers.
Preparation of Co-XG-GA
Xanthan gum and acacia gum, at concentrations of 3% each, were 
dispersed in distilled water. The xanthan gum and acacia gum were 
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mixed at varying ratios (1:1, 1:2, 2:1, 1:3, and 3:1) and homogenized 
with a rotation of 3000 rpm for 30 min to obtain a homogeneous 
mass. The mass was then dried with a double drum drier at 80±5°C. 
The obtained layer or flakes were milled and sieved using a 35 mesh. 
Chemical, physical, and functional characterizations of the mass were 
then performed.
Functional group analysis
Chemical characterization was performed by functional group analysis 
using infrared spectrophotometers. Several Co-XG-GA were weighed, 
mixed until homogeneous with dried KBr powder, and then scanned in 
the region of wavenumbers 4000–400 cm−1.
Particle size distribution
Particle size distribution was determined using a sieve method. The 
sieve was arranged from the smallest mesh of 35 mesh, followed by 
45 mesh, 60 mesh, 80 mesh, 120 mesh, and the largest at 230 mesh. 
The sample (25 g) was sieved with the smallest mesh at 30 rpm for 20 
min. Each sieve that contained powder was weighed. Then, the weight 
percentage of the powder was displayed on a particle size distribution 
diagram.
Thermal analysis
Physical characterization was performed by thermal analysis using 
a differential scanning calorimeter (DSC). Approximately 5 mg of the 
sample was placed into an aluminum cylinder with a diameter of 5 mm. 
The cylinder was covered with aluminum plates and then the sample 
was put into a DSC. Measurements were examined at 30–35°C with a 
heating rate of 10°C/min. Endothermic and exothermic processes that 
occurred in the sample were recorded [6].
Swelling index of floating tablets
The swelling index was performed using the powder excipient molded 
into a tablet with a weight of approximately 500 mg. The Petri dish and 
initial tablet (W1) were weighed. Each tablet was placed into a Petri dish 
containing 10 mL of HCl at pH 1.2. After 15 min, the HCl was removed 
from the Petri dish and carefully dried, and the tablet and Petri dish were 
weighed to obtain the weight of the hydrated tablets (W2). The same 
weighing procedure was performed at intervals of 30, 60, 120, 180, 240, 
360, 480, 600, and 720 min. The time taken during the weighing process 
was not counted as a time interval. The volume of the HCl medium must 
remain at 10 mL at the time of the swelling index to the next interval [7].
Gel strength test
The powder was dispersed in aquadest at a concentration of 10% w/v 
and heated at 120°C to form a gel. Measurements were performed using 
a texture analyzer (Rheoner 3305, Germany). The gel preparation was 
placed into the sample container and then the penetration device was 
lowered to the surface of the gel. The gel strength was then measured 
when the gel breaks.
Preparation of famotidine floating tablets
For the preparation of the famotidine floating tablets, the wet 
granulation method was adopted. Polymer powder, famotidine, and 
NaHCO3 were mixed until homogeneous. After that, talc, Mg stearate, 
and Avicel PH-101 were added and then molded manually using a tablet 
press machine. The composition of each formula is shown in Table 1.
Floating test
The tablets were placed in a 100 mL glass beaker containing simulated 
gastric fluid, pH 1.2 (HCl 0.1 N) at 37°C. The time required for the tablet 
to rise to the surface and to float was taken as the floating lag time 
(FLT). The duration of time in which the tablet constantly remained on 
the surface was considered as total floating time [8].
Famotidine content estimation in tablets
Three tablets of each formula were used to test for the drug content. 
Each tablet was crushed to a powder, weighed, and then placed 
into a 100 mL volumetric flask and dissolved with 0.1 N HCl. After 
that, the solution was filtered and diluted suitably. The absorbance 
of the resultant solution was then measured with ultraviolet (UV) 
spectrophotometer at a wavelength of 265 nm. The amount of drug 
contained in the sample was calculated with the help of a calibration 
curve from a standard solution [6].
Dissolution study
Dissolution apparatus type 1 (the basket type) was used for the 
dissolution study. A drug release study was performed using 900 mL 
0.1 N HCl at 37±0.5°C with a speed of 50 rpm. Sampling (10 mL) was 
performed at 15, 30, 60, 120, 180, 240, 360, 480, 600, and 720 min. 
The amount of solution taken was replaced by an equal amount of 0.1 
N HCl solution. The absorbance of the sample was measured with a UV 
spectrophotometer at a wavelength of 265 nm. The drug release profile 
was determined by plotting the percentage of drug released against 
time. The dissolution data obtained were then calculated to determine 
the kinetic model of drug release and the mechanism of release.
Drug release mechanism
The mechanism of drug release from the preparations was determined 
by plotting the dissolution data in kinetic models of zero order, first 




The percentage yields of the Co-XG-GA were 40–70%, as shown in 
Table 3. Weight loss occurred during the process of dispersing the 
Table 1: Formulas of famotidine floating tablets
Material F1 F2 F3 F4 F5 F6 F7 F8
Famotidine 40 40 40 40 40 40 40 40
Co-XG-GA (1:1) 300 - - - - - - -
Co-XG-GA (1:2) - 300 - - - - - -
Co-XG-GA (2:1) - - 300 - - - - -
Co-XG-GA (1:3) - - - 300 - - - -
Co-XG-GA (3:1) - - - - 300 - - -
Physical mixture of 
XG-GA
- - - - - 300 - -
Xanthan gum (XG) - - - - - - 300 -
Acacia gum (GA) - - - - - - - 300
NaHCO3 (15%) 75 75 75 75 75 75 75 75
Talc (2%) 10 10 10 10 10 10 10 10
Mg stearate (1%) 5 5 5 5 5 5 5 5
Avicel 101 70 70 70 70 70 70 70 70
Co-XG-GA: Coprocessed excipients of xanthan gum and acacia gum
Table 2: Drug release kinetic models
Model Equation
Zero order Qt/Q0=k0t
First order ln Qt/Q0=k1t
Higuchi Qt/Q0=kHt1/2
Korsmeyer–Peppas Qt/Q0=ktn
Qt/Q0: The drug fraction that is released at time t, k0, k1, kH, k: The drug release 
constants for each equation, n: Peppas diffusion exponent







Co-XG-GA: Coprocessed excipients of xanthan gum and acacia gum
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Fig. 2: Particle size distribution of coprocessed excipients of 
xanthan gum and acacia gum (Co-XG-GA) 1:1, Co-XG-GA 1:2, Co-XG-
GA 2:1, Co-XG-GA 1:3, and Co-XG-GA 3:1
Fig. 3: Endothermic and exothermic curves: (A) Coprocessed 
excipients of xanthan gum:acacia gum (Co-XG: GA) 1:1, (B) Co-
XG: GA 2:1, (C) Co-XG: GA 1:2, (D) XG, and (E) GA
Fig. 1: Infrared spectrum of excipients: (a) Xanthan gum, (b) acacia gum, (c) coprocessed excipients of xanthan gum and acacia gum (CO-
XG-GA) 1:1, (d) CO-XG-GA 1:2, and (e) CO-XG-GA 2:1
excipients in distilled water, along with material left behind during the 
drying, milling, and sifting process.
Functional group analysis
The purpose of the functional group analysis was to ascertain whether 
a chemical reaction occurred between each of the functional groups of 
the two excipients. Xanthan gum and acacia gum only interact or mix 
physically. No new functional groups presented in the spectrum (Fig. 1), 
indicating that these interactions do not involve chemical changes. The 
Fourier-transform infrared spectroscopy spectrum of xanthan gum, 
at wavenumber 1724.42 cm−1 showed a sharp peak, suggesting the 
presence of −C=O carboxylic bonds. This is reinforced by the presence 
of wide peaks with strong intensities in the range of wavenumbers 
2400–3700 cm−1, indicating the presence of the −OH carboxylate group.
Particle size distribution
The particle size distributions of the coprocessed excipients are shown 
in Fig. 2. The excipients of Co-XG-GA 1:1, Co-XG-GA 1:2, Co-XG-GA 2:1, 
Co-XG-GA 1:3, and Co-XG-GA 3:1 were distributed on the particle size of 
64–125 µm, with the percentages at 40.00%, 48.70%, 27.03%, 44.62%, 
and 26.27%, respectively. Particle size can affect the flowability of a 
powder: The smaller the particle size of the powder, the more difficult 
it is to flow, or it shows poor flow properties due to high interparticle 
cohesiveness.
Thermal analysis
Fig. 3 displays thermal analysis of the Co-XG-GA using DSC (PerkinElmer, 
USA). The results show that the Co-XG-GA 1:1, 1:2, and 2:1 excipients 
were first degraded at temperatures <100°C. According to the previous 
research, polysaccharides first degrade at a temperature of 40–110°C. 
Degradation at this temperature was associated with heat loss. Physical 
interactions involving high-temperature heating causes thermal 
stability to decrease [10]. The physical interaction of the polymer 
causes the formation of two descending peaks on the curve.
Swelling index
The results of the swelling index of the famotidine floating tablets are 
shown in Fig. 4. The Co-XG-GA excipient could swell for 12 h in HCl pH 
1.2. The Co-XG-GA 3:1 (F5) excipient had the highest swelling index 
at 307.35%, whereas the Co-XG-GA 1:3 (F4) excipient had the lowest 
swelling index at 131.16%. The Co-XG-GA 1:1 (F1), 1:2 (F2), and 2:1 
(F3) excipients had swelling indexes of 193.87%, 150.47%, and 
270.63%, respectively.
Gel strength test
Observation data on the strength of the excipient gel are shown in 
Table 4. The gel strength is the resistance of a gel to external pressure 
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and shows the nature of the cohesiveness of a gel in maintaining its 
shape.
Floating test
From the results of the floating test shown in Table 5, the F2 tablets 
composed of Co-XG-GA 1:2 excipient as the matrix had the fastest 
FLT value at 8.33 min. In contrast, the F5 tablets composed of Co-XG-
GA excipient 3:1 as a matrix had the longest FLT value of 15.67 min. 
The best formula was the F2 formula, which contained the Co-XG-GA 
1:2 excipient matrix on each tablet, and this formula had the fastest 
floating time among the five formulas at 8.33±0.58 min. This is because 
the Co-XG-GA 1:2 excipient was a combination of the natural polymers, 
which had a swelling index of 150.47% and a gel strength 14.67 gF; 
thus, it could absorb water immediately when in contact with the HCl 
at pH 1.2 medium [11]. This served to wet the gas-forming portion so 
that the formation of carbon dioxide gas was faster, which causes the 
preparation to float faster, and the resulting carbon dioxide gas can be 
retained by the Co-XG-GA 1:2 excipient matrix.
Famotidine content in the floating tablets
The famotidine content in the tablets is shown in Table 6 and is in the 
range of 90.0–110.0% and thereby meeting the requirements of the 
United States Pharmacopoeia 30th edition.
Drug release study
Fig. 5 shows the drug release profiles of the famotidine floating tablets. 
It shows that all the formulas that used a matrix of the coprocessed 
excipients could sustain drug release for 12 h with the cumulative 
amount released: F1 58.75%, F2 55.32%, F3 61.75%, F4 55.86%, F5 
61.65%, F6 63.59%, F7 74.75%, and F8 101.08%. The release profile 
of the famotidine floating tablets of formulas 1–5 followed by the zero-
order kinetics model and the drug release rate constants (k) is shown in 
Table 7. In this zero-order kinetics model, the drug release profile from 
the dosage form had a constant release rate from time to time without 
being affected by the concentration of the drug in the dosage form. This 
release kinetics model is also ideal for a controlled release dosage form 
because it can produce constant drug levels in the blood.
CONCLUSION
In this study, we produced the Co-XG-GA at ratios of 1:1, 1:2, 2:1, 1:3, and 































Fig. 4: Swelling index of the F1–F5 floating tablets for 12 h in 





































Fig. 5: The release profile of the famotidine floating tablets of 
F1–F5 formulation in HCl medium of pH 1.2 for 12 h, F6–F8 as 
a comparison. Each point represents the mean value±standard 
deviation (n=3)
Table 5: Floating lag time and total floating time of the 
famotidine floating tablets composed of the Co-XG-GA









Co-XG-GA: Coprocessed excipients of xanthan gum and acacia gum, FLT: Floating 
lag time, TFT: Total floating time
Table 4: Gel strength of the excipients
Material Gel strength (gF)
Co-XG: GA 1:1 17.5±0.87
Co-XG: GA 1:2 14.67±0.58
Co-XG: GA 2:1 32.67±1.53
Co-XG: GA 1:3 7.83±0.29
Co-XG: GA 3:1 36.17±0.76
Physical mixture 13.83±0.29
Xanthan gum (XG) 55.67±0.76
Acacia gum (GA) 0±0
Co-XG: GA: Coprocessed excipients of xanthan gum: acacia gum











Table 7:  Drug release rate constant (k) of the famotidine 
floating tablets
Formula Kinetics parameters






Int J App Pharm, Vol 12, Special Issue 1, 2020
 Budaya and Surini 
 The 4th International Conference on Global Health 2019 196
Co-XG-GA excipients had a characteristic swelling index and viscosity 
that were quite large, with gel strength of 7.83–36.17 gF; thus, this 
excipient was considered favorable for use in floating matrix tablets. 
The best formula was the second formula (F2), which contained a 1:2 
Co-XG-GA excipient matrix on each tablet and had the fastest floating 
time among the five formulas at 8.33±0.58 min, with drug release for 
8 h at 37.26%. All floating tablets with a Co-XG-GA excipient matrix 
showed a controlled release of famotidine over 24 h.
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